Physician profile
Stephen Trauzzi
NPI 1699711663
$9,297.14
in general payments reported to CMS, 2019-2025
34 companies · $952 in 2025
The $952 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,049 · 2020: $2,457 · 2021: $709 · 2022: $1,127 · 2023: $1,174 · 2024: $830 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635 · Education: $238 · Honoraria: $83.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.10 |
| Education | $237.97 |
| Honoraria | $83.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $2,008.39 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Astrazeneca Pharmaceuticals Lp | $1,303.75 | 2020 | |
| Sumitomo Pharma America, INC. | $1,067.94 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $718.97 | 2019-2023 | Erleada |
| Endo Pharmaceuticals INC. | $641.40 | 2019-2024 | Aveed, Edex, Xiaflex |
| Pfizer INC. | $531.14 | 2019-2025 | |
| Genzyme Corporation | $325.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $272.95 | 2019-2025 | |
| Myovant Sciences INC. | $241.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $226.36 | 2020-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Dendreon Pharmaceuticals LLC | $203.24 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $201.02 | 2019-2025 | Adstiladrin |
| Olympus America INC. | $186.55 | 2022-2025 | Itind System |
| Amgen INC. | $177.85 | 2019 | |
| Endo USA, INC. | $158.89 | 2024-2025 | Xiaflex, Aveed, Edex |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aytu Biopharma, INC. | $118.78 | 2019-2020 | |
| Comsort, INC | $100.00 | 2019 | |
| C. R. Bard, INC. & Subsidiaries | $83.00 | 2024 | |
| Progenics Pharmaceuticals, INC. | $78.95 | 2023 | Pylarify |
| Boston Scientific Corporation | $78.40 | 2019 | |
| Allergan, INC. | $62.68 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $59.99 | 2019 | |
| Tolmar, INC. | $57.56 | 2023-2024 | |
| Neotract INC. | $57.20 | 2019 | |
| Abbvie INC. | $55.71 | 2019-2020 | |
| Urovant Sciences INC | $49.48 | 2022 | |
| Coloplast Corp | $46.37 | 2019 | |
| Antares Pharma, INC. | $39.02 | 2019 | |
| Blue Earth Diagnostics | $31.71 | 2025 | Posluma |
| Medtronic USA, INC. | $25.83 | 2019 | |
| Lantheus Medical Imaging, INC. | $25.39 | 2024 | |
| Urogen Pharma, INC. | $23.92 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.19 | 2019 | |
| Avanos Medical | $16.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Trauzzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.